Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Efficacy of Fluoxetine Against Seizure-induced Central Apneas

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
状態完了
スポンサー
Hospices Civils de Lyon

キーワード

概要

Sudden unexpected death in epilepsy (SUDEP) is a tragic outcome of seizure disorders that primarily affect young adults suffering from refractory epilepsy. In this population, SUDEP incidence is estimated at 0.5%. While the mechanisms of SUDEP are not completely understood, it appears that the majority of such death occurs in the immediate aftermath of a general tonic-clonic seizure.
There is currently no validated preventive treatment for SUDEP. Some evidence suggest that modulation of the serotoninergic tone, and more specifically selective serotonin recapture inhibitor (SSRI) such as fluoxetine, might prevent SUDEP. Indeed, fluoxetine prevents seizure-induced lethal central apneas in DBA/2 and DBA/1 mice, one of the few animal models of SUDEP. Furthermore, serotoninergic bulbar nuclei are known to play a major role in the control of breathing, especially during sleep and in response to repeated hypoxia.
In patients with epilepsy undergoing in-hospital video-EEG monitoring, about one third of seizures are associated with decrease in SpO2 <90%, an abnormality suspected to represent a risk factor of SUDEP. In a retrospective uncontrolled study, patients treated with SSRIs displayed less frequent ictal/post-ictal hypoxemia than patients not taking SSRIs.
The investigators project aimed at testing whether fluoxetine can reduce the risk of ictal/post-ictal hypoxemia by performing a double-blind, randomized, placebo-controlled trial in patients undergoing video-EEG monitoring as part of the pre-surgical evaluation of their focal drug-resistant epilepsy.

日付

最終確認済み: 09/30/2016
最初に提出された: 09/23/2015
提出された推定登録数: 10/05/2015
最初の投稿: 10/06/2015
最終更新が送信されました: 10/03/2016
最終更新日: 10/04/2016
実際の研究開始日: 10/31/2010
一次完了予定日: 11/30/2010
研究完了予定日: 12/31/2014

状態または病気

Epilepsy
Ictal/Post-ictal Hypoxemia

介入/治療

Drug: FLUOXETINE

Drug: PLACEBO

段階

段階 3

アームグループ

介入/治療
Active Comparator: FLUOXETINE
4 weeks of treatment before video-EEG monitoring
Drug: FLUOXETINE
Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG. At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label.
Placebo Comparator: PLACEBO
1 month of treatment before EEG video.
Drug: PLACEBO
Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG. At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label.

適格基準

研究の対象となる年齢 18 Years に 18 Years
研究に適格な性別All
健康なボランティアを受け入れるはい
基準

Inclusion Criteria:

Patient suffering from drug-resistant focal epilepsy

- Age ≥ 18 years

- Patient for whom a video-EEG monitoring of their seizures was scheduled as part of a pre-surgical assessment

- For women of childbearing age, a method of contraception considered effective by the investigator

- Patient who have given their written informed consent

- Patient accepting an interview with a psychologist and to be refered to a psychiatrist in the event that mood disorders were detected on mood scores and considered severe by the investigator and / or psychologist, leading to require psychiatric care or immediate antidepressant treatment

- Patient with a social security number

Exclusion Criteria:

- Age < 18 years

- Patient under legal protection

- Pregnant or breastfeeding women

- Hypersensitivity to fluoxetine or its excipients

- History of other serious side effects related to an earlier prescription of fluoxetine;

- Current suicidal ideation or history of suicide attempt

- Manic episode

- Disruption of liver enzymes considered material by the investigator using the following criteria:

transaminases (ALT and AST)> 2N alkaline phosphatase (ALP)> 2N gamma glutamyl transpeptidase (GGT)> 5N (performed as part of routine monitoring of epileptic patients on antiepileptic treatment. Patients often exhibit changed deemed clinically insignificant due to the enzyme-inducing effect of these drugs)

- Renal failure with creatinine clearance <30 ml / min

- Acute heart disease

- Antidepressant treatment

- Other prohibited treatment (see detailed list in protocol).

結果

主な結果の測定

1. Ictal/post-ictal hypoxemia [Duration of video-EEG following 4 weeks of fluoxetine treatment]

Percentage of patients with at least one seizure associated with ictal/post-ictal SpO2 <90% in the group treated with fluoxetine compared to that receiving placebo.

二次的な結果の測定

1. Change in mood score with BDI-II score [After four weeks of treatment as compared to baseline]

Changes in score of BDI-II after four weeks of treatment as compared to baseline in the group treated with fluoxetine compared to that receiving placebo

2. Change in mood score with NDDIE score [After four weeks of treatment as compared to baseline]

Changes in score of NDDIE after four weeks of treatment as compared to baseline in the group treated with fluoxetine compared to that receiving placebo

3. Change in seizure frequency [After four weeks of treatment as compared to baseline]

Changes in seizure frequency after four weeks of treatment as compared to baseline in the group treated with fluoxetine compared to that receiving placebo

4. Change in sleep disorders score with SASDQ score [After four weeks of treatment as compared to baseline]

Changes in score of SASDQ after four weeks of treatment as compared to baseline in the group treated with fluoxetine compared to that receiving placebo

5. Change in sleep disorders score with EPWORTH score [After four weeks of treatment as compared to baseline]

Changes in score of EPWORTH after four weeks of treatment as compared to baseline in the group treated with fluoxetine compared to that receiving placebo

6. Change in score of quality of life [After four weeks of treatment as compared to baseline]

Change in score of QOLIE-89 after four weeks of treatment as compared to baseline in the group treated with fluoxetine compared to that receiving placebo

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge